A Human Pharmacological Study Comparing Conventional Heparin and a Low Molecular Weight Heparin Fragment

G Bratt; E Törnebohm; D Lockner; G Bergströ

doi:10.1055/s-0038-1661275

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1985; 53(02): 208-211
DOI: 10.1055/s-0038-1661275

Original Article

Schattauer GmbH Stuttgart

A Human Pharmacological Study Comparing Conventional Heparin and a Low Molecular Weight Heparin Fragment

G Bratt

The Thrombosis Unit, Section of Hematology, Department of Internal Medicine, Huddinge University Hospital, Huddinge, Sweden

,

E Törnebohm

The Thrombosis Unit, Section of Hematology, Department of Internal Medicine, Huddinge University Hospital, Huddinge, Sweden

,

D Lockner

The Thrombosis Unit, Section of Hematology, Department of Internal Medicine, Huddinge University Hospital, Huddinge, Sweden

,

G Bergströ

¹Department of Clinical Chemistry, Huddinge University Hospital, Huddinge, Sweden

› Institutsangaben

Abstract

als PDF herunterladen

Summary

The pharmacokinetics of a heparin fragment of low molecular weight (LMWH) of 4000-5000 D and unfractioned standard heparin (UFH) have been studied after i. v. injections of different doses and infusions in 8 humans.

The heparin activity was significantly higher and the effect on APTT lower after LMWH fragment as compared to UFH in the same doses.

The half-life of heparin activity was about 1 hr for UFH and about 2 hr for LMWH. LMWH was found to be eliminated according to first order kinetics and there were no signs of dose dependency.

Keywords

Heparin - Low molecular weight heparin - Pharmacokinetics - Humans

PDF (357 kb)

Referenzen

References
1 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
2 Höök M, Björk I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Letters 1976; 66: 90-93
3 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
4 Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIa, Factor XHa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400
5 Oosta GM, Gardner WT, Beeler DL, Rosenberg RD. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 1981; 78: 829-833
6 Choay J, Lormeau JC, Petitou M, Sinay P, Casu B, Oreste P, Torri G, Gatti G. Anti-Xa active heparin oligosaccharides. Thromb Res 1980; 18: 573-578
7 Yin ET, Wessler S, Stoll PJ. Biological properties of the naturally occurring plasma inhibitor to activated factor X. J Biol Chem 1971; 246: 3703-3711
8 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
9 Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemostas 1981; 45: 214-218
10 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of a low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
11 Esquivel CO, Bergqvist D, Björck C-G, Nilsson B. Comparison between commercial heparin, low-molecular-weight heparin and pentosan polysulphate on hemostasis and platelets in vivo. Thromb Res 1982; 28: 389-399
12 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
13 Fabris F, Fussi F, Casonato A, Visentin L, Randi M, Smith MR, Girolami A. Normal and low molecular weight heparins: Interaction with human platelets. Eur J Clin Invest 1983; 13: 135-139
14 Kapsch DN, Adelstein EH, Rhodes GR, Silver D. Heparin-induced thrombocytopenia, thrombosis and hemorrhage. Surgery 1979; 86: 148-155
15 Mastacchi R, Stanzani L, Barbanti M, Montecchi L, Bianchini P. Interaction of Heparin and Heparin fractions with human platelets. Thromb Res 1982; 28: 275-280
16 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low-molecular-weight heparin and prevention of post-operative deep vein thrombosis. Br Med J 1982; 284: 375-379
17 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified antithrombin III Thromb Res 1977; 10: 399-410
18 Ødegård OR, Lie M, Abildgaard U. Heparin co-factor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294
19 Born GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
20 Cipolle RJ, Randall DS, Neilan BA, Zaske DE, Haus E. Heparin kinetics: Variables related to disposition and dosage. Clin Pharmacol Ther 1981; 29: 387-393
21 Björnsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982; 31: 104-113
22 de Swart CA M, Nijmeyer B, Roelofs JM M, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258
23 Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. Acta Med Scand 1963; 173: 619-630
24 Estes JW. The fate of heparin in the body. Curr Ther Res 1975; 18: 45-57
25 MacAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. J Pharmakokinetic Biopharm 1979; 7: 331-354
26 Holmer E, Lindahl U, Bäckström G, Thunberg L, Sandberg H, Söderström G, Andersson L-O. Anticoagulant activities and effects of platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-869